证券代码： 301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------------|------------------------------------------------------|--------------------------| | | | | 编号：投-004 | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 √ | 业绩说明会 | | | 类别 | □新闻发布会 □ | 路演活动 | | | | □现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称及 | | | | | 人员姓名 | 线上参与公司泰恩康 | 2022 年度网上业绩说明会的投资者 | | | 时间 | 2023 年 05 月 16 | 日（星期二）下午 15:00-16:00 | | | 地点 | "泰恩康投资者关系"微信小程序 | | | | 上市公司接待人 | 董 ...

证券代码：301263 证券简称：泰恩康 公告编号：2023-035 广东泰恩康医药股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）已于2023年04月27日在 巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年05 月16日（星期二）15:00至16:00时在"泰恩康投资者关系"小程序举行2022年度 网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登 陆"泰恩康投资者关系"小程序参与互动交流。为广泛听取投资者的意见和建议， 提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"泰恩康投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"泰恩康投资者关系"小程序，即可参与交 流。 出席本次网上业绩说明会的人员有：公司董事长、总经理郑汉 ...

证券代码： 301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 编号：投-003 | --- | --- | --- | |----------------|----------------------------|--------------| | | □特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □媒体采访 | □ 业绩说明会 | | 类别 | □新闻发布会 | □ 路演活动 | | | □现场参观 | | | | √ 其他（电话会议） | | | | 方正证券研究所章钟涛 | 唐爱金 | | | 兴证全球基金管理有限公司 | 谢长雁 | | | 宝盈基金管理有限公司 | 吕姝仪 | | | 华夏基金管理有限公司 | 李平祝 | | | 中海基金梁静静 | | | | 天弘基金管理有限公司 | 郭相博 | | | 景顺长城李南西 | | | | 睿远基金吴蔽野 | | | | 中加基金管理有限公司 | 温燕 | | | 中融基金周桓 | | | | 东方红马庆华 | | | 参与单位名称及 | 金信基金谭智汨 | | | 人员姓名 | 中信资管倪秉泽 | | ...

Financial Performance - The company's operating revenue for 2022 was ¥783,480,165.06, representing a 19.86% increase compared to ¥653,651,415.43 in 2021[5]. - Net profit attributable to shareholders for 2022 was ¥174,614,590.33, a 45.43% increase from ¥120,065,941.64 in 2021[5]. - The net cash flow from operating activities was ¥148,814,836.05, up 23.99% from ¥120,023,212.46 in the previous year[5]. - The basic and diluted earnings per share for 2022 were both ¥0.79, reflecting a 16.18% increase from ¥0.68 in 2021[5]. - Total assets at the end of 2022 reached ¥2,038,804,786.88, a significant increase of 116.54% from ¥941,522,180.98 at the end of 2021[5]. - The company's total revenue for 2022 reached ¥783,480,165.06, representing a year-on-year increase of 19.86% compared to ¥653,651,415.43 in 2021[84]. - The pharmaceutical manufacturing segment saw a significant revenue increase of 30.49%, totaling ¥360,854,604.49, while the pharmaceutical agency segment grew by 7.20% to ¥387,745,096.48[84]. - The gross profit margin for the pharmaceutical manufacturing segment improved to 61.04%, an increase of 8.08% from the previous year[87]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[178]. Product Development and R&D - The company is focused on expanding its product offerings and enhancing its R&D capabilities to mitigate market risks[4]. - The company has developed multiple innovative drug projects, including polymer micelles for injection formulations, indicating a strong focus on R&D in chronic disease management[30]. - The company has 34 ongoing self-developed pharmaceutical projects, with 6 having submitted drug registration applications, indicating a strong pipeline for future product approvals[31]. - The company aims to enhance collaboration with research institutions and innovative companies to expand its product offerings and leverage its retail channel advantages[31]. - The company is actively expanding its product pipeline, with 34 major self-developed pharmaceutical projects, 6 of which have submitted drug registration applications[72]. - The company plans to continue increasing R&D investments, with expectations of launching more than two self-developed drugs annually over the next three years[82]. - Research and development investment amounted to ¥54,037,400, marking a 49.76% increase year-on-year, with 34 major self-developed pharmaceutical projects currently in progress[82]. - The company is committed to research and development of new products and technologies to maintain competitive advantage[170]. - The company is investing in research and development for new products aimed at improving healthcare solutions[145]. Market Trends and Opportunities - The two-sex health medication market is rapidly growing, driven by changing societal attitudes and increasing health demands, with significant potential for PE and ED treatment drugs[35]. - The ophthalmic medication market in China saw sales exceeding 12 billion CNY in 2021, with a year-on-year growth of 15.01%, indicating a robust demand for eye care products[36]. - The gastrointestinal medication market in China was approximately 30 billion CNY in retail sales in 2021, with a compound annual growth rate of 5.75% from 2018 to 2021[39]. - The Chinese traditional medicine market is projected to exceed 110 billion CNY in sales in 2022, supported by government initiatives to promote traditional medicine[40]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[178]. Governance and Compliance - The company has a comprehensive governance structure with all board members present for the report's approval[4]. - The company maintains independent operations from its controlling shareholders and actual controllers, ensuring no interference in management[153]. - A transparent performance evaluation and incentive mechanism for senior management has been established, linking compensation to company performance[155]. - The company has established a complete corporate governance structure in compliance with the Company Law and Securities Law, ensuring independent operation of its functional departments[163]. - The company has a dedicated financial department and an independent financial accounting system, allowing for independent financial decision-making[162]. Risks and Challenges - The company acknowledges potential risks including R&D risks, drug market entry risks, and registration renewal risks for imported drugs[4]. - The company faces risks related to R&D failures, which could impact the recovery of investments and overall profitability[139]. - There is a risk that newly developed drugs may not meet market demands or face competition from similar products, affecting the company's revenue[140]. - The stability of the company's agency operations is crucial for its revenue, with potential risks if agreements with suppliers are not maintained[141]. - The company must ensure timely re-registration of imported drug certificates to avoid disruptions in production and operations[143]. Strategic Initiatives - The company plans to distribute a cash dividend of 7.00 RMB per 10 shares (including tax) to all shareholders, based on a total of 236,387,500 shares[4]. - The company has established three major pharmaceutical R&D technology platforms, including functional excipients and nanomedicine[53]. - The company aims to strengthen its R&D capabilities, focusing on innovative drug research and development, with an emphasis on functional excipients and nanomedicine technologies[135]. - The company plans to enhance its digital platforms to better serve its customer base and improve operational efficiency[145]. - The company is actively seeking partnerships with other firms to leverage synergies in product development and market expansion[145]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,002, with 386 in the parent company and 616 in major subsidiaries[196]. - The company has established a comprehensive salary management system and implements a performance appraisal system to enhance employee satisfaction and align with corporate goals[198]. - Employee training programs are conducted across multiple levels and formats, focusing on new employee orientation, on-the-job training, and management skills enhancement[199]. - The company has a structured approach to employee training, aiming to improve overall employee quality and innovation capabilities[199]. - The company has seen a shift in its management structure to better align with its strategic goals and market demands[169].

Financial Performance - The company's revenue for Q1 2023 was CNY 193,788,912.58, representing a 5.73% increase compared to CNY 183,290,412.29 in the same period last year[5]. - Net profit attributable to shareholders decreased by 3.51% to CNY 51,985,920.77 from CNY 53,875,611.94 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 11.88% to CNY 46,808,747.53 compared to CNY 53,120,767.73 in the previous year[5]. - The total operating revenue for Q1 2023 was CNY 193,788,912.58, an increase of 5.6% compared to CNY 183,290,412.29 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 51,674,794.42, a decrease of 4.1% from CNY 53,874,484.71 in Q1 2022[26]. - The total comprehensive income attributable to the parent company is CNY 51,876,683.00, down from CNY 54,106,652.71, reflecting a decline of approximately 4.3%[27]. - Basic and diluted earnings per share for Q1 2023 are both CNY 0.22, compared to CNY 0.30 in the previous period, indicating a decrease of 26.7%[27]. Assets and Liabilities - The company's total assets increased by 7.04% to CNY 2,182,265,103.71 from CNY 2,038,804,786.88 at the end of the previous year[5]. - The total liabilities as of March 31, 2023, were CNY 250,024,516.91, compared to CNY 184,843,822.55 at the start of the year[23]. - The company's cash and cash equivalents decreased to CNY 553,119,978.27 from CNY 806,786,386.60 at the beginning of the year[21]. - The company's inventory increased to CNY 93,157,668.83 from CNY 80,523,332.56 at the beginning of the year, indicating a potential increase in production or sales[22]. Cash Flow - Cash flow from operating activities decreased by 2.27% to CNY 43,734,808.96 compared to CNY 44,750,344.20 in the previous year[5]. - Cash inflow from operating activities totals CNY 187,555,195.15, an increase from CNY 167,719,799.27, representing a growth of 11.0%[30]. - The net cash flow from operating activities is CNY 43,734,808.96, slightly down from CNY 44,750,344.20, a decrease of 2.3%[30]. - Cash outflow from investing activities is CNY 723,535,880.95, significantly higher than CNY 12,493,985.79 in the previous period, indicating increased investment activity[30]. - The net cash flow from investing activities is -CNY 296,882,888.97, compared to -CNY 12,493,485.79, reflecting a larger cash outflow[30]. - The net cash flow from financing activities is -CNY 516,082.76, a decrease from CNY 1,060,775,223.32 in the previous period, indicating reduced financing activity[31]. - The ending cash and cash equivalents balance is CNY 553,069,978.27, down from CNY 1,229,499,447.67, a decline of 55.0%[31]. Research and Development - Research and development expenses surged by 141.08% to CNY 15,898,325.39 from CNY 6,594,626.38 in the same period last year, indicating increased investment in R&D[12]. - Research and development expenses for Q1 2023 were CNY 15,898,325.39, significantly higher than CNY 6,594,626.38 in Q1 2022, reflecting a focus on innovation[26]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,519[14]. - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[14]. - Major shareholder Sun Weiwen holds 15.56% of shares, totaling 36,787,150 shares[14]. - The total number of restricted shares at the beginning of the period was 182,722,522, with 73,558,710 shares released during the period[17]. - The company has a total of 109,163,812 restricted shares remaining at the end of the period[17]. - The top ten shareholders hold a significant portion of the company's equity, with the largest shareholder holding over 20%[14]. - The company has established relationships among major shareholders, indicating potential coordinated actions[15]. Acquisitions and Market Expansion - The company plans to acquire 50% equity of Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd[18]. - The company completed the acquisition of a 50% stake in Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd. for CNY 200 million, enhancing its product pipeline[19]. - The company is exploring market expansion opportunities through acquisitions and partnerships[18]. Goodwill - The company reported a significant increase in goodwill by 634.24% to CNY 200,643,602.10 due to acquisitions made during the reporting period[9]. - The company reported a significant increase in goodwill to CNY 200,643,602.10 from CNY 27,326,563.93, indicating potential acquisitions or investments[22].

Financial Performance - Revenue for Q3 2022 reached ¥198,658,228.89, an increase of 30.92% year-over-year[7] - Net profit attributable to shareholders was ¥49,601,390.11, up 123.79% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥45,622,308.85, reflecting a growth of 111.19% year-over-year[7] - Basic earnings per share for Q3 2022 was ¥0.21, up 61.54% from the same period last year[7] - For the first three quarters of 2022, the company reported total revenue of CNY 573.43 million, up 22.47% year-on-year[29] - The net profit attributable to shareholders for the first three quarters was CNY 127.16 million, an increase of 60.21% compared to the previous year[29] - The company reported a total comprehensive income of ¥127,739,140.77, up from ¥79,453,880.62, marking an increase of 60.8%[52] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,985,620,844.01, representing a 110.89% increase from the previous year[7] - Shareholders' equity reached ¥1,807,036,365.30, a significant rise of 154.53% compared to the end of the previous year[7] - The total assets of the company reached CNY 1.99 billion as of September 30, 2022, compared to CNY 941.52 million at the start of the year[40] - Total equity attributable to shareholders of the parent company increased significantly to ¥1,807,036,365.30 from ¥709,958,986.51, representing a growth of 154.5%[46] Cash Flow - Cash flow from operating activities for the year-to-date was ¥97,054,451.32, an increase of 70.49% year-over-year[7] - Net cash flow from operating activities rose by 70.49% to ¥97,054,451.32, primarily driven by increased cash receipts from sales[16] - Operating cash inflow totaled $571,083,668.76, an increase from $450,506,088.42 in the previous period, reflecting a growth of approximately 27%[57] - The net cash flow from financing activities was $893,059,310.56, contrasting with a net outflow of -$28,849,751.10 in the previous period, highlighting improved financial stability[60] - The company reported a net increase in cash and cash equivalents of $288,199,555.88, compared to a decrease of -$11,424,367.63 previously, indicating a positive cash position[60] Investments and Expenses - The company reported a 426.32% increase in contract assets, totaling ¥15,996,718.49, due to progress in R&D projects[12] - Management expenses increased by 30.03% to ¥41,727,809.43 due to higher employee compensation and listing-related costs[16] - Financial expenses decreased by 66.07% to ¥1,163,180.07 as a result of reduced bank loan interest after repayment[16] - Investment income surged by 2016.84% to ¥1,969,614.16 due to increased returns from financial products purchased with idle funds[16] - Research and development expenses rose to ¥25,220,770.88, an increase of 13.5% compared to ¥22,318,014.11 in the previous year[47] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,418[20] - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[20] Tax and Liabilities - The company reported a 76.34% increase in income tax expenses to ¥23,848,515.01 due to profit growth[16] - Total liabilities decreased to ¥178,728,524.91 from ¥231,714,080.57, reflecting a reduction of approximately 22.9%[46] Product Performance - The core product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) generated sales of CNY 163.84 million, a 65.87% increase year-on-year[32] - The "He Wei Zheng Chang Wan" (Stomach and Intestine Pills) achieved sales of CNY 100.87 million, growing by 26.75% year-on-year[32] - The company is facing supply chain challenges for its core product "He Wei Zheng Chang Wan" due to domestic pandemic fluctuations and logistics issues[32]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[21]. - The net profit attributable to shareholders was RMB 80 million, up 20% compared to the same period last year[21]. - The company's operating revenue for the reporting period was ¥374,774,136.13, representing an increase of 18.42% compared to the same period last year[30]. - The net profit attributable to shareholders was ¥77,557,085.13, reflecting a growth of 35.58% year-over-year[30]. - The net profit after deducting non-recurring gains and losses was ¥73,995,209.37, which is an increase of 58.43% compared to the previous year[30]. - The basic earnings per share increased to ¥0.37, up 15.63% from ¥0.32 in the same period last year[33]. - The core product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) generated sales revenue of 105.51 million yuan, a significant increase of 42.66% compared to the same period last year[77]. - The sales revenue of "He Wei Zheng Chang Wan" (Stomach and Intestine Pills) increased by 23.52% year-on-year, reaching 61.85 million yuan[77]. Research and Development - The company plans to invest RMB 100 million in R&D for new drug development in the next fiscal year[21]. - The company has established three major pharmaceutical R&D technology platforms to support its development efforts[44]. - The company’s R&D investment reached 20.26 million yuan, representing a year-on-year growth of 16.35%[79]. - The company plans to continue increasing R&D investment, anticipating that more than 2 self-developed drugs will receive registration approval annually over the next three years[79]. - The company focuses on enhancing its new drug research capabilities, leveraging functional excipients, nanomedicine technology platforms, and biosimilar drug development to strengthen its competitive edge and market expansion[132]. Market Expansion - User data indicates a 25% increase in the number of active customers, reaching 1 million by the end of June 2022[21]. - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 30%[21]. - The company aims to launch two new products by the end of 2022, targeting a market share increase of 10% in the respective segments[21]. - The company’s marketing network covers 28 provincial regions in China, supported by over 300 professional sales personnel[78]. - The company has established long-term partnerships with major pharmaceutical distribution companies, enhancing its market reach and sales capabilities[78]. Product Development - The company's self-developed product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) accounted for 45.55% of total revenue in the first half of 2022[44]. - The newly approved "Aiting Wei" (Tadalafil Tablets) was launched in August 2022, expected to leverage existing marketing channels for rapid market penetration[79]. - The company’s main products include "Aiting Jiu" Dapoxetine Hydrochloride Tablets and "Aiting Wei" Tadalafil Tablets, both classified as prescription drugs for male sexual health[52]. - The company’s ophthalmic product "Woliting" is specifically designed for various retinal diseases, indicating a focus on specialized treatments[50]. Financial Management - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥304,843,771.43, a rise of 2,882.66% compared to ¥10,220,524.28 in the previous year, mainly due to funds raised from the initial public offering[93]. - The company's total assets included cash and cash equivalents of ¥442,473,163.91, representing 22.86% of total assets, a 221.50% increase from the previous year[98]. - The company’s financial expenses decreased by 73.09% to ¥512,413.13, down from ¥1,903,853.87 in the previous year, due to reduced interest expenses after repaying bank loans[93]. - The company raised a total of ¥117,786.30 million from its initial public offering, with a net amount of ¥105,208.07 million after deducting issuance costs[12]. Environmental Compliance - The company has focused on environmental protection and compliance, with all subsidiaries achieving standard emissions during the reporting period[157]. - The company’s subsidiary, Tai En Kang Pharmaceutical Factory, has implemented measures to ensure that emissions meet standards, including VOCs treatment and wastewater management[158]. - The wastewater from Tai En Kang Pharmaceutical Factory meets the second-stage tertiary standard limits for water pollutants[158]. - The company has taken measures to reduce noise pollution from production equipment, ensuring compliance with industrial noise emission standards[160]. Related Party Transactions - The company reported a total of 210.77 million yuan in related party transactions during the reporting period, with 98.70% attributed to product sales[182]. - The company confirmed that all related party transactions were conducted at market prices and did not deviate from market rates[182]. - The approved transaction limit for related party transactions was 1,470 million yuan, and the actual transactions did not exceed this limit[182].

Financial Performance - Revenue for Q1 2022 reached ¥183,290,412.29, an increase of 30.81% compared to ¥140,121,443.95 in Q1 2021[6] - Net profit attributable to shareholders was ¥53,875,611.94, up 210.80% from ¥17,334,683.77 in the same period last year[6] - Net profit excluding non-recurring gains and losses was ¥53,120,767.73, a significant increase of 443.40% from ¥9,775,568.58[6] - Basic earnings per share rose to ¥0.30, a 200.00% increase compared to ¥0.10 in the previous year[6] - The total operating revenue for the first quarter was 161,943,777.06 CNY, an increase from 137,190,552.45 CNY in the previous year, representing a growth of approximately 18.1%[41] - The net profit attributable to the parent company was 53,875,611.94 CNY, compared to 17,334,683.77 CNY in the same period last year, showing a significant increase of about 210.5%[38] - The operating profit reached 67,938,498.88 CNY, up from 18,612,655.99 CNY, indicating a growth of approximately 264.5%[35] - The total comprehensive income for the period was 54,110,240.60 CNY, compared to 17,288,809.87 CNY last year, representing an increase of about 213.5%[38] Cash Flow and Assets - Operating cash flow for Q1 2022 was ¥44,750,344.20, representing a 93.11% increase from ¥23,173,961.87 in Q1 2021[6] - Cash and cash equivalents increased significantly to ¥1,230,639,921.12 from ¥137,629,392.48, reflecting a growth of 794.5%[26] - Total assets at the end of Q1 2022 were ¥2,072,058,906.42, up 120.08% from ¥941,522,180.98 at the end of the previous year[6] - Total liabilities increased to ¥256,059,862.49 from ¥231,714,080.57, an increase of 10.5%[32] - Owner's equity surged to ¥1,815,999,043.93 from ¥709,808,100.41, reflecting a growth of 156.7%[32] - The net cash flow from operating activities was 44,750,344.20 CNY, compared to 23,173,961.87 CNY in the previous year, reflecting an increase of about 93.1%[41] - The cash flow from investment activities was a net outflow of $12,493,485.79, compared to a net outflow of $8,790,045.11 previously[44] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,685, with the largest shareholder, Zheng Hanjie, holding 20.77% of shares, equating to 49,098,900 shares[15] - The second-largest shareholder, Sun Weiwen, holds 15.56% of shares, totaling 36,787,150 shares[15] - The top five shareholders collectively hold 55.19% of the company's shares, indicating a significant concentration of ownership[15] - The company has a total of 29,677,000 shares held by other pre-IPO shareholders, which are subject to unlocking conditions[22] - The company has a total of 2,789,785 shares from other offline placement shareholders that are restricted until September 29, 2022[22] IPO and Market Presence - The company has received approval from the China Securities Regulatory Commission for its initial public offering, with shares listed on the Shenzhen Stock Exchange on March 29, 2022[23] - The company issued 50,875,193 shares during its IPO, which began trading on March 29, 2022[25] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[6] Other Financial Metrics - Research and development expenses decreased to 6,594,626.38 CNY from 8,132,315.41 CNY, a reduction of approximately 18.9%[35] - The total operating costs amounted to 114,284,847.76 CNY, compared to 129,513,142.95 CNY in the previous year, indicating a decrease of approximately 11.7%[35] - The tax expenses for the period were 13,819,361.84 CNY, significantly higher than 1,917,340.72 CNY from the previous year, reflecting an increase of about 620.5%[35] - Other income decreased to 1,394,977.91 CNY from 8,565,938.76 CNY, a decline of approximately 83.7%[35] Share Restrictions and Unlocking - The company has a total of 177,287,500 restricted shares at the beginning of the period, with 2,789,807 shares added during the period, resulting in a total of 180,077,307 restricted shares by the end[22] - The company plans to unlock 49,098,900 shares held by Zheng Hanjie and 36,787,150 shares held by Sun Weiwen on March 29, 2025[22] Audit Status - The first quarter report was not audited[45]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year growth of 15%[23]. - The net profit attributable to shareholders was 150 million RMB, an increase of 20% compared to the previous year[23]. - The company's operating revenue for 2021 was ¥653.65 million, a decrease of 7.80% compared to ¥708.98 million in 2020[29]. - The net profit attributable to shareholders for 2021 was ¥120.07 million, down 25.34% from ¥160.83 million in 2020[29]. - The net profit after deducting non-recurring gains and losses was ¥108.27 million, a decrease of 29.13% compared to ¥152.76 million in 2020[29]. - The sales revenue from the mask business in 2021 was 39.80 million yuan, a decline of 83.37% compared to 2020, significantly impacting overall revenue and net profit[99]. - Excluding mask business revenue, the company's pharmaceutical agency operations and self-produced product revenue grew by 13.34% and 23.94% respectively compared to 2020[99]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[200]. Dividend and Cash Flow - The company plans to distribute a cash dividend of 3.50 RMB per 10 shares, totaling approximately 82.3 million RMB[6]. - The net cash flow from operating activities for 2021 was ¥120.02 million, a decrease of 4.38% from ¥125.53 million in 2020[29]. - The company reported a net cash flow from operating activities of ¥120,023,212.46 in 2021, a decrease of 4.38% compared to 2020[131]. - The net cash flow from investing activities decreased by 52.17% to -44,286,860.31 compared to the previous year[134]. - The net cash flow from financing activities increased by 67.97% to -31,543,708.95, primarily due to increased cash payments for debt repayment[134]. - The net increase in cash and cash equivalents rose by 217.33% to 44,116,284.22, attributed to reduced cash payments for fixed asset construction[135]. Research and Development - The company has invested 100 million RMB in R&D for new product development, focusing on innovative drug formulations[23]. - The company invested ¥36.08 million in R&D in 2021, with 21 major self-developed projects, of which 6 have submitted drug registration applications[101]. - Research and development investment has increased by 30%, focusing on advanced drug formulations and delivery systems[200]. - The company has established three major pharmaceutical research and development technology platforms, enhancing its capabilities in chemical raw materials, chemical preparations, and biological drugs[46]. - The company has established three major pharmaceutical R&D technology platforms, including functional excipients and nano-drug delivery key technology platform[70]. - The company has a strong R&D advantage with 21 major pharmaceutical projects, of which 6 have submitted drug registration applications[90]. Market Expansion and Strategy - Future outlook includes an expected revenue growth of 10% for 2022, driven by market expansion and new product launches[23]. - The company is exploring potential acquisitions to enhance its market presence and product portfolio[23]. - A new marketing strategy has been implemented, targeting a 30% increase in market penetration in the next fiscal year[23]. - The company aims to focus on the development and sales of self-researched drugs, with expectations for steady revenue growth from these products as market sales continue to increase[47]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next year through strategic partnerships and marketing initiatives[200]. - The company plans to expand its sales network, particularly in underrepresented regions, to enhance market coverage and improve service capabilities[155]. Product Development and Sales - The self-developed product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) was approved for sale in 2020, marking it as the first domestic product to meet the quality consistency evaluation requirements of the original research drug, achieving a revenue contribution of 42.30% from self-developed products in 2021[46][47]. - The sales revenue of "Aiting Jiu" dapoxetine hydrochloride tablets reached 152.31 million yuan in 2021, an increase of 167.34% year-on-year, making it a core product[99]. - The sales revenue of "He Wei Zheng Chang Wan" was 115.79 million yuan, up 21.58% year-on-year, while "Wo Li Ting" achieved sales of 202.66 million yuan, a growth of 19.46%[99]. - The company plans to launch tadalafil tablets in 2022, which will synergize with its existing product "Aiting Jiu" to enhance profitability[101]. - The company is preparing to launch clinical trials for HKS01, a treatment for age-related macular degeneration, which has completed small and pilot studies[123]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management and pricing strategies[23]. - The company aims to enhance operational efficiency, targeting a 15% reduction in production costs through process optimization[200]. - The company's operating costs for 2021 increased by 1.79% year-on-year, primarily due to the rise in pharmaceutical agency revenue leading to higher costs[112]. Market Trends and Opportunities - The gastrointestinal drug retail market in China was approximately 26.94 billion yuan in 2020, with a compound annual growth rate of 7.40% from 2017 to 2020, indicating significant market potential for gastrointestinal medications[54]. - The market for two-sex health medications is experiencing rapid growth, driven by changing societal attitudes and increasing health awareness, presenting substantial potential for the company’s products in this segment[51]. - The eye care medication market is expanding, with a compound annual growth rate of 11.66% from 2011 to 2019, reflecting a growing demand for eye care products due to increased awareness and prevalence of eye diseases[52]. - The traditional Chinese medicine market is expected to grow significantly due to increasing global interest and supportive government policies, providing further opportunities for the company[58]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking compensation to company performance and individual performance[178]. - The company maintains complete independence in assets, operations, personnel, finance, and institutions from its controlling shareholders and actual controllers[180]. - The company has a governance structure that complies with relevant laws and regulations, ensuring no significant discrepancies with regulatory requirements[179]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[173]. Challenges and Risks - The company faces risks related to R&D failures, market acceptance of new drugs, and potential disruptions in its agency operations[162][164].